Myeloid and monocytic dyspoiesis detected by flow cytometry
. | Patient group . | . | . | . | . | . | |||||
---|---|---|---|---|---|---|---|---|---|---|---|
Flow cytometric abnormality . | MDS (n = 115) . | Aplastic anemia (n = 26) . | Nonhematopoietic malignancies (n = 15) . | Hodgkin disease (n = 26) . | Bone marrow transplant donors with cytopenias (n = 37) . | All non-MDS subjects (n = 104) . | |||||
Abnormal myeloblasts, no. (%) | 72 (62) | 0 (0)* | 0 (0)* | 0 (0)* | 1 (3)* | 1 (1)* | |||||
Maturing myeloid | |||||||||||
Abnormal granularity | 9 (8) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0)* | |||||
Abnormal decrease CD45 | 4 (3) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | |||||
Abnormal relationship CD13/CD16 | 27 (23) | 3 (12) | 0 (0)* | 3 (12) | 6 (16) | 12 (12)* | |||||
Abnormal relationships | |||||||||||
HLA-DR/CD11b | 6 (5) | 0 (0) | 0 (0) | 1 (4) | 1 (3) | 2 (2) | |||||
Asynchronous shift to the left | 26 (23) | 0 (0)* | 0 (0)* | 0 (0)* | 0 (0)* | 0 (0)* | |||||
Presence of CD56 | 18 (16) | 1 (4) | 1 (7) | 6 (23) | 0 (0)* | 8 (8) | |||||
Lack of CD33 | 6 (5) | 1 (4) | 0 (0) | 0 (0) | 3 (8) | 4 (4) | |||||
Presence of CD34 | 7 (6) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0)* | |||||
Presence of lymphoid antigens | 4 (3) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | |||||
Monocytes | |||||||||||
Abnormal granularity | 1 (1) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | |||||
Lack of CD13 or CD16 | 1 (1) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | |||||
Abnormal relationship HLA-DR/CD11b | 5 (4) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | |||||
Presence of CD56 | 19 (17) | 0 (0)* | 0 (0) | 3 (12) | 0 (0)* | 3 (3)* | |||||
Lack of CD33 or CD14 | 3 (3) | 0 (0) | 0 (0) | 0 (0) | 0 (0)* | 0 (0) | |||||
Presence of CD34 | 14 (12) | 0 (0) | 0 (0) | 0 (0) | 0 (0)* | 0 (0)* | |||||
Presence of lymphoid antigens | 4 (3) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | |||||
Abnormal L/M ratio | 38 (33) | 19 (73)† | 1 (7)* | 0 (0)* | 1 (3)* | 21 (20)* | |||||
Abnormal cytogenetics | 71 (62)‡ | 0 (0)* | 0 (0)* | 1 (4)* | 0 (0)* | 1 (1)* |
. | Patient group . | . | . | . | . | . | |||||
---|---|---|---|---|---|---|---|---|---|---|---|
Flow cytometric abnormality . | MDS (n = 115) . | Aplastic anemia (n = 26) . | Nonhematopoietic malignancies (n = 15) . | Hodgkin disease (n = 26) . | Bone marrow transplant donors with cytopenias (n = 37) . | All non-MDS subjects (n = 104) . | |||||
Abnormal myeloblasts, no. (%) | 72 (62) | 0 (0)* | 0 (0)* | 0 (0)* | 1 (3)* | 1 (1)* | |||||
Maturing myeloid | |||||||||||
Abnormal granularity | 9 (8) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0)* | |||||
Abnormal decrease CD45 | 4 (3) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | |||||
Abnormal relationship CD13/CD16 | 27 (23) | 3 (12) | 0 (0)* | 3 (12) | 6 (16) | 12 (12)* | |||||
Abnormal relationships | |||||||||||
HLA-DR/CD11b | 6 (5) | 0 (0) | 0 (0) | 1 (4) | 1 (3) | 2 (2) | |||||
Asynchronous shift to the left | 26 (23) | 0 (0)* | 0 (0)* | 0 (0)* | 0 (0)* | 0 (0)* | |||||
Presence of CD56 | 18 (16) | 1 (4) | 1 (7) | 6 (23) | 0 (0)* | 8 (8) | |||||
Lack of CD33 | 6 (5) | 1 (4) | 0 (0) | 0 (0) | 3 (8) | 4 (4) | |||||
Presence of CD34 | 7 (6) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0)* | |||||
Presence of lymphoid antigens | 4 (3) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | |||||
Monocytes | |||||||||||
Abnormal granularity | 1 (1) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | |||||
Lack of CD13 or CD16 | 1 (1) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | |||||
Abnormal relationship HLA-DR/CD11b | 5 (4) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | |||||
Presence of CD56 | 19 (17) | 0 (0)* | 0 (0) | 3 (12) | 0 (0)* | 3 (3)* | |||||
Lack of CD33 or CD14 | 3 (3) | 0 (0) | 0 (0) | 0 (0) | 0 (0)* | 0 (0) | |||||
Presence of CD34 | 14 (12) | 0 (0) | 0 (0) | 0 (0) | 0 (0)* | 0 (0)* | |||||
Presence of lymphoid antigens | 4 (3) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | |||||
Abnormal L/M ratio | 38 (33) | 19 (73)† | 1 (7)* | 0 (0)* | 1 (3)* | 21 (20)* | |||||
Abnormal cytogenetics | 71 (62)‡ | 0 (0)* | 0 (0)* | 1 (4)* | 0 (0)* | 1 (1)* |
The data field shows the number with percentage in parentheses.
Number of abnormalities are significantly lower than MDS patients (P of a 2-sided Fisher exact test < .05).
Number of abnormalities is significantly higher than MDS patients (P of a 2-sided Fisher exact test < .05).
One patient missing cytogenetic data.